Skip to main content
. 2016 Mar 8;7(16):22339–22354. doi: 10.18632/oncotarget.7970

Figure 7. miR-101 inhibits EMT in TGF-β-treated GBC cells.

Figure 7

Representative figures and data from transwell assays A. and wound healing assays B. conducted using GBC cells transfected with miR-101 and/or TGF-β for 24 h (**P<0.01). C. E-cadherin, β-catenin, vimentin, p-Smad2, p-c-Raf, MEK1/2, p-MEK1/2, Erk1/2, and p-Erk1/2 expression was analyzed by western blot analysis in cells transfected with miR-101 and/or TGF-β for 24 h. β-actin was used as a loading control. D. A hypothetical model illustrating the role of miR-101 on GBC cells.